Oxytrol is a brand name of oxybutynin, approved by the FDA in the following formulation(s):
OXYTROL (oxybutynin - film, extended release; transdermal)
Manufacturer: WATSON LABS (UTAH)
Approval date: February 26, 2003
Strength(s): 3.9MG/24HR [RLD]
Has a generic version of Oxytrol been approved?
No. There is currently no therapeutically equivalent version of Oxytrol available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oxytrol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Triacetin as a penetration enhancer for transdermal delivery of a basic drug
Patent 5,601,839
Issued: February 11, 1997
Inventor(s): Quan; Danyi & Deshpanday; Ninad A. & Venkateshwaran; Srinivasan & Ebert; Charles D.
Assignee(s): TheraTech, Inc.
A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of penetration enhancer consisting essentially of triacetin, and a polymer later preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.
Patent expiration dates:
Triacetin as a penetration enhancer for transdermal delivery of a basic drug
Patent 5,834,010
Issued: November 10, 1998
Inventor(s): Quan; Danyi & Deshpanday; Ninad A. & Venkateshwaran; Srinivasan & Ebert; Charles D.
Assignee(s): Theratech, Inc.
A composition and method for enhancing transdermal penetration of a basic drug are described. The composition comprises a matrix patch comprising an effective amount of a basic drug, preferably having a pK.sub.a of about 8.0 or greater, an effective amount of a penetration enhancer consisting essentially of triacetin, and a polymer layer preferably comprising a pressure-sensitive adhesive. A preferred basic drug is oxybutynin and acid addition salts thereof. The method for enhancing transdermal penetration comprises applying the matrix patch to a selected area of skin.
Patent expiration dates:
Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Patent 6,743,441
Issued: June 1, 2004
Inventor(s): Steven W.; Sanders & Charles D.; Ebert
Assignee(s): Watson Pharmaceuticals, Inc.
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Patent expiration dates:
Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Patent 7,081,249
Issued: July 25, 2006
Inventor(s): Sanders; Steven W. & Ebert; Charles D.
Assignee(s): Watson Laboratories, Inc.
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Patent expiration dates:
Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Patent 7,081,250
Issued: July 25, 2006
Inventor(s): Sanders; Steven W. & Ebert; Charles D.
Assignee(s): Watson Laboratories, Inc.
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Patent expiration dates:
Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Patent 7,081,251
Issued: July 25, 2006
Inventor(s): Sanders; Steven W. & Ebert; Charles D.
Assignee(s): Watson Laboratories, Inc.
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Patent expiration dates:
Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Patent 7,081,252
Issued: July 25, 2006
Inventor(s): Sanders; Steven W. & Ebert; Charles D.
Assignee(s): Watson Laboratories, Inc.
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Patent expiration dates:
Compositions and methods for transdermal oxybutynin therapy
Patent 7,179,483
Issued: February 20, 2007
Inventor(s): Ebert; Charles D. & Sanders; Steven W.
Assignee(s): Watson Pharmaceuticals, Inc.
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
Patent expiration dates:
See also...
- Oxytrol Consumer Information (Drugs.com)
- Oxytrol System Consumer Information (Wolters Kluwer)
- Oxytrol transdermal Consumer Information (Cerner Multum)
- Oxytrol Advanced Consumer Information (Micromedex)
- Oxybutynin Consumer Information (Drugs.com)
- Oxybutynin Consumer Information (Wolters Kluwer)
- Oxybutynin Extended-Release Tablets Consumer Information (Wolters Kluwer)
- Oxybutynin Gel Consumer Information (Wolters Kluwer)
- Oxybutynin Syrup Consumer Information (Wolters Kluwer)
- Oxybutynin System Consumer Information (Wolters Kluwer)
- Oxybutynin Consumer Information (Cerner Multum)
- Oxybutynin topical Consumer Information (Cerner Multum)
- Oxybutynin transdermal Consumer Information (Cerner Multum)
- Oxybutynin Advanced Consumer Information (Micromedex)
- Oxybutynin Transdermal Advanced Consumer Information (Micromedex)
- Oxybutynin Chloride AHFS DI Monographs (ASHP)
